---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-038497"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T03:16:51.115888+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics stockholders approve share issuance and equity plan increase at special meeting

## Summary
- Ratified Wolf & Company as independent auditor for 2024, with 8.32M votes for.
- Approved issuance of common stock upon conversion of Series A and B preferred and warrants.
- Approved issuance under Committed Equity Financings arrangement.
- Amended 2024 Equity Incentive Plan, increasing authorized shares by 2,000,000.
- All proposals passed with over 98% of votes cast in favor; quorum of 56.9% of shares.

## SEC filing metadata
- accession: 0001213900-24-038497
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390024038497/0001213900-24-038497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390024038497/ea0205118-8k_cerothera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-038497
- JSON: https://secwatch.observer/filing/0001213900-24-038497.json
- Plain text: https://secwatch.observer/filing/0001213900-24-038497.txt

## Key facts
- Shareholder Votes
  CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To approve an amendment to the Company’s 2024 Equity Incentive Plan (the “Plan”), as amended, amended to increase the number of shares of Common Stock available for issuance under the Plan and the number of shares that may be issued pursuant to incentive stock options by an additional 2,000,000 shar at the 2024-04-30 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2024-04-30
  source text: Proposal 4. To approve an amendment to the Company’s 2024 Equity Incentive Plan (the “Plan”), as amended, amended to increase the number of shares of Common Stock available for issuance under the Plan and the number of shares that may be issued pursuant to incentive stock options by an additional 2,000,000 shares. FOR ABSTAIN AGAINST 8,234,447 5,614 134,041
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390024038497/0001213900-24-038497-index.htm
- Shareholder Votes
  CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To approve, subject to certain conditions, the issuance of the Common Stock, in accordance with Nasdaq Listing Rule 5635, upon (i) the conversion of the Company’s Series A convertible preferred stock, par value $0.0001 per share (“Series A Preferred Stock”), (ii) the conversion of the Company’s Seri at the 2024-04-30 meeting.
  - Outcome: passed
  - Meeting: 2024-04-30
  source text: Proposal 2. To approve, subject to certain conditions, the issuance of the Common Stock, in accordance with Nasdaq Listing Rule 5635, upon (i) the conversion of the Company’s Series A convertible preferred stock, par value $0.0001 per share (“Series A Preferred Stock”), (ii) the conversion of the Company’s Series B convertible preferred stock, par value $0.0001 per share, (iii) the exercise of warrants to purchase Common Stock and (iv) the exercise of warrants to purchase 2,500 shares of Series A Preferred Stock and conversion of the underlying Series A Preferred Stock. FOR ABSTAIN AGAINST 8,308,766 6,621 58,715
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390024038497/0001213900-24-038497-index.htm
- Shareholder Votes
  CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To approve, subject to certain conditions, the issuance of shares of Common Stock, in accordance with Nasdaq Listing Rule 5635, pursuant to the Committed Equity Financings (as defined in the Proxy Statement). at the 2024-04-30 meeting.
  - Outcome: passed
  - Meeting: 2024-04-30
  source text: Proposal 3. To approve, subject to certain conditions, the issuance of shares of Common Stock, in accordance with Nasdaq Listing Rule 5635, pursuant to the Committed Equity Financings (as defined in the Proxy Statement). FOR ABSTAIN AGAINST 8,303,706 6,581 63,815
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390024038497/0001213900-24-038497-index.htm
- Shareholder Votes
  CERO THERAPEUTICS HOLDINGS, INC. shareholders approved To ratify the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the 2024 fiscal year. at the 2024-04-30 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2024-04-30
  source text: Proposal 1. To ratify the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the 2024 fiscal year. FOR ABSTAIN AGAINST 8,321,662 7,562 44,878
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390024038497/0001213900-24-038497-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.